Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297433 | 0.85 | KMT2A (0.54) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL532700 | 0.82 | TSHR (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL28882390 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL16644078 | 0.79 | KMT2A (0.53) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4771370 | 0.78 | ALDH1A1 (0.53) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL319866 | 0.77 | KMT2A (0.73) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12332347 | 0.77 | ALDH1A1 (0.45) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1948128 | 0.76 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL9008302 | 0.76 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13104661 | 0.76 | ALDH1A1 (0.47) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-3733675-A1 | SALT CRYSTALS OF A PDE1 INHIBITOR | Intra-Cellular Therapies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-3274352-B1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma AG (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-3274352-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2001029010-A1 | GRAM-POSITIVE SELECTIVE ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0442473-B1 | Pyrimidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5162326-A | Antagonists for angeotensin; hypotensive agents; treatment for heart diseases, strokes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0442473-A1 | Pyrimidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | ADORA2A, ADORA2B, ADORA3 | KMT2A 1020/4885MEN1 2383/4885CYP1A2 725/4885 |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | ADORA2A, ADORA2B, ADORA3 | KMT2A 1020/4885MEN1 2383/4885CYP1A2 725/4885 |
| US-20070021422-A1 | Prokineticin 1 receptor | PROKR1, PROKR2, GIPR | KMT2A 4529/4885MEN1 292/4885CYP1A2 3130/4885 |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | KMT2A 1465/4885MEN1 2494/4885CYP1A2 533/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | KMT2A 2310/4885MEN1 1334/4885CYP1A2 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.